Main news

                                    PRESS RELEASE OF THE CARDIOPROGRESS FOUNDATION

                  Main results of the XI International Forum

                     for Cardiology and Internal Medicine

Nobel Prize in Physiology or Medicine 2025
Nobel Prize in Physiology or Medicine 2025 The Nobel Prize in Physiology or Medicine 2025 was awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi "for their discoveries concerning peripheral immune tolerance.


World Heart day 2025
World Heart day 2025 World Heart Day is celebrated annually on September 29. Since its inception, the Cardioprogress Foundation has actively collaborated with the World Heart Federation and, to celebrate this occasion, organizes events in various cities across the Russian Federation.


Editorial Activity

cardiology book

AHA Flags Barriers to Women in Interventional Specialties
AHA Flags Barriers to Women in Interventional Specialties A new scientific statement from the American Heart Association (AHA) addresses barriers to entry and retention of women in interventional vascular fields, including interventional cardiology, interventional radiology, and vascular surgery, and proposes potential solutions.


New Marker of Cardiovascular Risk Discovered in T2D
New Marker of Cardiovascular Risk Discovered in T2D A significant quantity of dysfunctional monocytes appears to indicate poor cardiovascular prognosis in patients with type 2 diabetes.


New Score Predicts Risk for Death on Heart Transplant List
New Score Predicts Risk for Death on Heart Transplant List Allocation score, called the US candidate risk score (US-CRS), outperformed the current therapy-based 6-status system in rank ordering heart transplant candidates by medical urgency.


Near-Death Experiences During CPR: An Impetus for Better Care
Near-Death Experiences During CPR: An Impetus for Better Care If someone has been in cardiac arrest for 10 minutes, the brain is permanently damaged and there's nothing to do, right? Not so according to emerging evidence that suggests that the brain shows signs of electrical recovery for as long as an hour into ongoing cardiopulmonary resuscitation (CPR). This time between cardiac arrest and awakening can be a period of vivid experiences for the dying patient before they return to life — a phenomenon known as "recalled death."


Novel Biomarkers for Aortic Stenosis Identified
Novel Biomarkers for Aortic Stenosis Identified A new analysis that used plasma proteomics, cardiac imaging, and event surveillance of participants in a longitudinal cohort study identified 52 circulating proteins with significant links to aortic valve (AV) hemodynamics and the risk for AV-related hospitalizations. Two of these biomarkers had particularly robust associations.


Recommendations for magnetic resonance imaging in patients with cardiac implantable electronic devices
Recommendations for magnetic resonance imaging in patients with cardiac implantable electronic devices Over the last several decades, magnetic resonance (MR) imaging has become the diagnostic modality of choice for several conditions, cardiac and non-cardiac. However, MR uses a static magnetic field, gradient magnetic fields and pulsed radiofrequency energy, all of which may interact with metallic and electronic components within the field. As such, patients with cardiac implantable electronic devices (CIEDs) have traditionally been precluded from MR imaging given the potential harm from mechanical force and torque, heating and tissue damage, unwanted myocardial stimulation or electrical reset.


Cancer Identified as a New Cardiovascular Risk Factor
Cancer Identified as a New Cardiovascular Risk Factor A history of cancer is an independent predictor of major cardiovascular events in patients undergoing coronary angioplasty. Cancer should be considered a new cardiovascular risk factor in primary and secondary prevention.


Management of arrhythmogenic right ventricular cardiomyopathy
Management of arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a disease characterised by fibrofatty replacement of the ventricular myocardium due to specific mutations, leading to ventricular arrhythmias and sudden cardiac death. Treating this condition can be challenging due to progressive fibrosis, phenotypic variations and small patient cohorts limiting the feasibility of conducting meaningful clinical trials.